Skip to main content

Table 1 Baseline characteristics

From: Safety and feasibility of contained uterine morcellation in women undergoing laparoscopic hysterectomy

Characteristic

Leiomyoma (N = 35)

Uterine Cancer (N = 53)

Age

48 ± 6.5 [range 36–60]

60.1 ± 9.9 [range 38–81]

Race/ethnicity

 Caucasian

27 (77.1)

29 (54.7)

 African American

5 (14.3)

23 (43.4)

 Asian

0 (0)

1 (1.9)

 Hispanic

2 (5.7)

0 (0)

 Other

1 (2.9)

0 (0)

BMI

32.8 ± 9.2 [range 19.7–56.3]

37.5 ± 11.0 [range 19.2–64.5]

Paritya

1.5 ± 1.0 [range 0–3]

1.9 ± 1.8 [range 0–7]

Pre-op uterine size estimate (weeks)b

15.1 ± 2.7 [range 10–20]

10.7 ± 2.7 [range 6–14]

Menopausal

7 (20)

40 (75.5)

Prior Abdominal Surgery

23 (65.7)

27 (50.9)

Pre-op Diagnosis

 Leiomyoma

33 (94.3)

6 (11.3)

 Endometrial cancer

0

50 (94.3)

 Ovarian cyst/mass

10 (30.3)

2 (3.8)

 Otherc

10 (30.3)

7 (13.2)

  1. Data are n(%) or mean ± SD unless otherwise specified. Data are presented as two separate cohorts given different disease states
  2. aMissing data: n = 34 for leiomyoma group
  3. bMissing data: n = 21 for leiomyoma group, n = 17 for uterine cancer group
  4. cIncludes endometrial intraepithelial neoplasia (3), abnormal uterine bleeding (4), family history of cancer (1), terminal ileum cancer (1), anemia (1), breast cancer (1), pelvic pain (1) and history of rectovaginal fistula repair (1) in the leiomyoma group and postmenopausal bleeding (2), atypical glandular cells (2), cirrhosis (1), cervical stenosis (2), chronic kidney disease (1), ventral hernia (1), atypical spindle cells (1) and pelvic organ prolapse (1) for the endometrial cancer group